| 证券代码 | CYTR.O |
| 证券名称 | 赛特科科技 |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 1986-11-14 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | USD |
| 公司名称 | CytRx Corporation |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 11726 San Vicente Blvd, Suite 650, Los Angeles, California, USA |
| 成立日期 | 1985 |
| 董事会主席 | Steven A. Kriegsman |
| 公司属地 | United States 美国 |
| 公司网址 | www.cytrx.com |
| 电话 | +1 (310) 826-5648 |
| 传真 | +1 (310) 826-6139 |
| 公司简介 | CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. It currently is focused on the clinical development of aldoxorubicin, its modified version of the widely-used chemotherapeutic agent, doxorubicin. Aldoxorubicin combines the chemotherapeutic agent doxorubicin with a novel linker-molecule that binds specifically to albumin in the blood to allow for delivery of higher amounts of doxorubicin without several of the major dose-limiting toxicities seen with administration of doxorubicin alone. |